MCID: THY028
MIFTS: 69

Thyroid Cancer malady

Categories: Cancer diseases, Genetic diseases, Endocrine diseases

Aliases & Classifications for Thyroid Cancer

Aliases & Descriptions for Thyroid Cancer:

Name: Thyroid Cancer 12 52 41 14
Thyroid Carcinoma 12 24 29 52 14 69
Thyroid Gland Neoplasm 12 29
Thyroid Neoplasm 12 69
Malignant Neoplasm of Thyroid Gland 12
Malignant Tumour of Thyroid Gland 12
Head and Neck Cancer, Thyroid 12
Malignant Neoplasm of Thyroid 69
Neoplasm of Thyroid Gland 12
Thyroid Neoplasms 42

Classifications:



External Ids:

Disease Ontology 12 DOID:1781 DOID:3963
ICD10 33 C73
ICD9CM 35 193
MeSH 42 D013964

Summaries for Thyroid Cancer

MedlinePlus : 41 your thyroid is a butterfly-shaped gland in your neck, just above your collarbone. it makes hormones that help the body work normally. there are several types of cancer of the thyroid gland. you are at greater risk if you are between ages 25 and 65 are a woman are asian have a family member who has had thyroid disease have had radiation treatments to your head or neck you should see a doctor if you have a lump or swelling in your neck. doctors use a physical exam, thyroid tests, other blood and imaging tests, and a biopsy to diagnose thyroid cancer. treatment depends on the type of cancer you have and how far the cancer has spread. many patients receive a combination of treatments. they may include surgery, radioactive iodine, hormone treatment, radiation therapy, chemotherapy, or targeted therapy. targeted therapy uses substances that attack cancer cells without harming normal cells. nih: national cancer institute

MalaCards based summary : Thyroid Cancer, also known as thyroid carcinoma, is related to endemic goiter and testicular cancer, and has symptoms including coughing, snoring and sore throat. An important gene associated with Thyroid Cancer is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are Thyroid cancer and MAPK-Erk Pathway. The drugs Cometriq and Lenvima have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and endothelial, and related phenotypes are Decreased viability and homeostasis/metabolism

Disease Ontology : 12 A thyroid cancer that has material basis in epithelial cells.

Wikipedia : 71 Thyroid cancer is a cancer originating from follicular or parafollicular thyroid cells. These cells give... more...

Related Diseases for Thyroid Cancer

Diseases related to Thyroid Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 225)
id Related Disease Score Top Affiliating Genes
1 endemic goiter 30.1 CALCA TG TPO TSHR
2 testicular cancer 29.2 BRAF CDH1 KRAS NKX2-1
3 thyroid cancer, monmedullary, 1 12.2
4 thyroid cancer, nonmedullary, 2 12.2
5 thyroid cancer, nonmedullary, 5 12.2
6 thyroid cancer, anaplastic 12.1
7 thyroid cancer, nonmedullary, 4 12.1
8 thyroid cancer, childhood 11.9
9 medullary thyroid carcinoma, familial 11.7
10 thyroid carcinoma, hurthle cell 11.6
11 thyroiditis 11.1
12 hypothyroidism 11.0
13 familial papillary thyroid carcinoma 11.0
14 ntrk1-related familial medullary thyroid carcinoma 10.8
15 pulmonary arteriovenous malformation 10.7
16 multiple endocrine neoplasia iia 10.7
17 thyroid sarcoma 10.7
18 secondary hypereosinophilic syndrome 10.4 FOXE1 HABP2
19 fasting plasma glucose level qtl 5 10.4 HABP2 NTRK1 RET
20 parietal lobe neoplasm 10.3 CALCA FOXE1 TG
21 endophthalmitis 10.3 CALCA TG
22 cowden syndrome 3 10.3 CALCA RET TG
23 trigonocephaly, nonsyndromic 10.3 BRAF RET
24 bizarre leiomyoma 10.3 CALCA NKX2-1 TG
25 urinary tract papillary transitional cell benign neoplasm 10.3 CALCA NKX2-1 RET
26 background diabetic retinopathy 10.3 TG TPO TSHR
27 dysautonomia, familial 10.3 FOXE1 TG TPO
28 mesocardia 10.3 FOXE1 PAX8 TG TSHR
29 conjunctival deposit 10.3 TG TPO TSHR
30 mixed eosinophil-basophil adenoma 10.3 TG TPO TSHR
31 hypothyroidism, congenital, nongoitrous, 1 10.3 TG TPO TSHR
32 tmem70 defect 10.3 BRAF NKX2-1 PAX8 RET TG
33 pseudomonas stutzeri infections 10.3 BRAF KRAS NRAS
34 premature closure of the arterial duct 10.3 SLC5A5 TG TPO
35 rdh12-related leber congenital amaurosis 10.3 BRAF KRAS NRAS
36 acute hemorrhagic encephalitis 10.3 HRAS NRAS RET TG TSHR
37 denys-drash syndrome 10.3 TG TPO TSHR
38 erythrocyte lactate transporter defect 10.3 HRAS KRAS NRAS
39 syndactyly-polydactyly-earlobe syndrome 10.3 BRAF HRAS KRAS
40 melanocytic nevus syndrome, congenital, somatic 10.3 HRAS KRAS NRAS
41 janus kinase-3 deficiency 10.3 TG TPO TSHR
42 kidney clear cell sarcoma 10.3 HRAS KRAS NKX2-1
43 malignant skin fibrous histiocytoma 10.3 HRAS KRAS
44 uterine corpus endometrial stromal sarcoma 10.3 HRAS KRAS PAX8
45 ossifying fibromyxoid tumor 10.3 HRAS KRAS NRAS
46 childhood teratocarcinoma of the testis 10.3 CALCA RET TG
47 spongiotic dermatitis 10.3 HRAS KRAS NRAS
48 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 3 10.3 BRAF HRAS LGALS3 NRAS
49 vascular hemostatic disease 10.3 HRAS KRAS RET
50 dihydrolipoamide dehydrogenase deficiency 10.3 PAX8 TG TPO

Comorbidity relations with Thyroid Cancer via Phenotypic Disease Network (PDN):


Hypertension, Essential Hypothyroidism
Lymphomatous Thyroiditis Postsurgical Hypothyroidism

Graphical network of the top 20 diseases related to Thyroid Cancer:



Diseases related to Thyroid Cancer

Symptoms & Phenotypes for Thyroid Cancer

UMLS symptoms related to Thyroid Cancer:


coughing, snoring, sore throat, vertigo/dizziness, equilibration disorder

GenomeRNAi Phenotypes related to Thyroid Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.95 KRAS BRAF HRAS
2 Decreased viability GR00106-A-0 9.95 KRAS
3 Decreased viability GR00221-A-1 9.95 KRAS NRAS CDH1 PPARG RET HRAS
4 Decreased viability GR00221-A-2 9.95 KRAS PPARG RET HRAS
5 Decreased viability GR00221-A-3 9.95 NRAS PPARG NTRK1 HRAS
6 Decreased viability GR00221-A-4 9.95 BRAF PPARG RET
7 Decreased viability GR00231-A 9.95 RET
8 Decreased viability GR00301-A 9.95 KRAS BRAF CDH1 RET NTRK1
9 Decreased viability GR00381-A-1 9.95 KRAS BRAF

MGI Mouse Phenotypes related to Thyroid Cancer:

44 (show all 19)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.43 BRAF CDH1 FOXE1 HABP2 HRAS KRAS
2 growth/size/body region MP:0005378 10.39 CDH1 FOXE1 HRAS KRAS NKX2-1 NRAS
3 endocrine/exocrine gland MP:0005379 10.37 TPO TSHR BRAF CDH1 FOXE1 HRAS
4 mortality/aging MP:0010768 10.33 BRAF CDH1 FOXE1 HABP2 HRAS KRAS
5 behavior/neurological MP:0005386 10.32 BRAF HRAS KRAS LGALS3 NKX2-1 NRAS
6 cardiovascular system MP:0005385 10.27 NRAS PAX8 PPARG RET BRAF CDH1
7 immune system MP:0005387 10.25 BRAF CDH1 HABP2 KRAS LGALS3 NRAS
8 digestive/alimentary MP:0005381 10.17 BRAF CDH1 FOXE1 KRAS LGALS3 NKX2-1
9 integument MP:0010771 10.15 FOXE1 HRAS KRAS LGALS3 NRAS NTRK1
10 nervous system MP:0003631 10.14 TG TSHR BRAF HRAS KRAS LGALS3
11 neoplasm MP:0002006 10.13 BRAF CDH1 HRAS KRAS LGALS3 NKX2-1
12 hearing/vestibular/ear MP:0005377 10.08 BRAF KRAS NTRK1 PAX8 PPARG TPO
13 limbs/digits/tail MP:0005371 10.02 KRAS NRAS NTRK1 PAX8 RET TPO
14 no phenotypic analysis MP:0003012 10.02 CDH1 HRAS KRAS NKX2-1 NRAS NTRK1
15 normal MP:0002873 10.02 BRAF CDH1 HRAS KRAS NKX2-1 NRAS
16 reproductive system MP:0005389 9.81 LGALS3 NKX2-1 PAX8 PPARG RET TSHR
17 renal/urinary system MP:0005367 9.8 BRAF HRAS KRAS LGALS3 PAX8 PPARG
18 skeleton MP:0005390 9.61 LGALS3 NKX2-1 PAX8 PPARG TPO TSHR
19 vision/eye MP:0005391 9.23 BRAF KRAS NRAS NTRK1 PAX8 PPARG

Drugs & Therapeutics for Thyroid Cancer

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Cometriq 17 46 CABOZANTINIB S-MALATE Exelixis Approved November 2012
2
Lenvima 17 46 LENVATINIB MESYLATE Eisai Approved February 2015
3
Nexavar 17 46 SORAFENIB TOSYLATE Bayer/Onyx Approved December 2005
4
Vandetanib 17 46 vandetanib AstraZeneca Approved April 2011

Drugs for Thyroid Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 473)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754 657311
2
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 1 53-03-2 5865
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 50-02-2 5743
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
5
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
6
Diazepam Approved, Illicit, Vet_approved Phase 4,Phase 1 439-14-5 3016
7
Hydroxocobalamin Approved Phase 4,Phase 2 13422-51-0 11953898 5460373 44475014
8
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
9
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
10
rituximab Approved Phase 4,Phase 3,Phase 2 174722-31-7 10201696
11
Exemestane Approved, Investigational Phase 4 107868-30-4 60198
12
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
13
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
15
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
16
Cyanocobalamin Approved, Nutraceutical Phase 4,Phase 2 68-19-9 44176380
17
Manganese Approved, Nutraceutical Phase 4 7439-96-5 27854
18
Butyric Acid Experimental Phase 4 107-92-6 264
19 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
20 Anti-Infective Agents, Local Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
21 cadexomer iodine Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
22
Iodine Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 7553-56-2 807
23 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
24 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
25 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1
26 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 1
27 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Cortisol succinate Phase 4
29 glucocorticoids Phase 4,Phase 2,Phase 1
30 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
31 Hormones Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
33 Hydrocortisone 17-butyrate 21-propionate Phase 4
34 Hydrocortisone acetate Phase 4
35 Hydrocortisone-17-butyrate Phase 4
36 Imatinib Mesylate Phase 4,Phase 2,Phase 1 123596
37 Analgesics Phase 4,Phase 3,Phase 2
38 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
39 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
40 BB 1101 Phase 4,Phase 2,Phase 1
41 Dexamethasone 21-phosphate Phase 4,Phase 2,Phase 1
42 Dexamethasone acetate Phase 4,Phase 2,Phase 1 1177-87-3
43 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
45 Vitamins Phase 4,Phase 3,Phase 2,Phase 1
46 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 1
47 Respiratory System Agents Phase 4,Phase 3,Phase 1
48 Antiemetics Phase 4,Phase 2,Phase 1
49 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1
50 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 693)
id Name Status NCT ID Phase
1 rAd-p53 Gene Therapy for Advanced Malignant Thyroid Tumors Unknown status NCT00902122 Phase 4
2 Total Thyroidectomy With Harmonic Scalpel® Unknown status NCT00385983 Phase 4
3 Comparison of the Vocal Cord Imaging Techniques After Thyroidectomy Unknown status NCT02410928 Phase 4
4 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4
5 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4
6 Dental Safety Profile of High-Dose Radioiodine Therapy Completed NCT00439478 Phase 4
7 Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer Completed NCT00604318 Phase 4
8 A Retrospective Observational Study Comparing Two Different Treatment Options in Thyroid Cancer Patients With T4 Tumours Completed NCT01736163 Phase 4
9 Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal. Completed NCT00001730 Phase 4
10 Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia Completed NCT01308320 Phase 4
11 Is the Routine Pressure Dressing After Thyroidectomy Necessary? Completed NCT00400465 Phase 4
12 Percutaneous Laser Ablation in Benign Thyroid Nodules.Long Term Results Completed NCT00858104 Phase 4
13 Phase 4 Study in Secondary Hypothyroidism: Body Weight Adapted Thyroxin Treatment and Triiodothyronine Supplementation Completed NCT00360074 Phase 4
14 Myo-inositol Versus D-chiro-inositol in the Treatment of Polycystic Ovary Syndrome and Insulin Resistance: Evaluation of Clinical, Metabolic, Endocrine and Ultrasound Parameters Completed NCT01514942 Phase 4
15 Radiolabeled Molecules for Medullary Thyroid Cancer Recruiting NCT01915485 Phase 4
16 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4
17 Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy Recruiting NCT02946918 Phase 4
18 Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy Recruiting NCT02652884 Phase 4
19 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4
20 Aromasin® Non-Interventional Study Of Early Invasive Breast Cancer Patients In China Recruiting NCT01176916 Phase 4
21 Effect of Nasal CPAP on Lipid Profile in Patients With Dyslipidaemia and Sleep Apnea Recruiting NCT02557412 Phase 4
22 To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer Active, not recruiting NCT01496313 Phase 4
23 Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients Unknown status NCT00435851 Phase 3
24 Efficacy of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy Unknown status NCT02112370 Phase 3
25 Medico-economic Evaluation Comparing the Use of Ultrasonic Scissors to the Conventional Techniques of Haemostasis in Thyroid Surgery by Cervicotomy Unknown status NCT01551914 Phase 3
26 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3
27 Improved Preoperative Selection of Cold Thyroid Nodules Unknown status NCT00297297 Phase 3
28 Laser Therapy of Benign Thyroid Nodules Unknown status NCT00150150 Phase 3
29 Thyroxin Treatment in Sub Clinical Hypothyroidism, on the Apnea Hypopnea Index Score, Lipids and Highly Sensitive CRP Unknown status NCT01486667 Phase 3
30 Decision Making on Radioactive Iodine Treatment for Papillary Thyroid Cancer Completed NCT01083550 Phase 2, Phase 3
31 The Usefulness of Staining Lymph Nodes During Operations for Cancer Thyroid in Detecting the Nodes That Have Cancer Completed NCT00794053 Phase 3
32 A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. Completed NCT00295763 Phase 3
33 Multicenter Study Differentiated Thyroid Carcinoma Completed NCT00144079 Phase 3
34 rhTSH-Thyroid Ablation With 1850 MBq of 131I Completed NCT00454077 Phase 3
35 Lateral Neck Sentinel Lymph Node Biopsy(LSLNB)in PTC Completed NCT01137097 Phase 2, Phase 3
36 Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration Completed NCT00196729 Phase 3
37 Efficacy of Subfascial Approach in Thyroidectomy to Quality of Life in Thyroid Disease Patients Completed NCT01616316 Phase 2, Phase 3
38 Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma Completed NCT00795782 Phase 3
39 Efficacy of Fibrin Sealant to Reduce the Amount of Post-thyroidectomy Drain Completed NCT01126060 Phase 3
40 Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer Completed NCT00123760 Phase 2, Phase 3
41 Cinacalcet to Treat Familial Primary Hyperparathyroidism Completed NCT00325104 Phase 3
42 Percutaneous Radiofrequency Thermal Ablation in Compressive Thyroid Nodules Completed NCT01649206 Phase 3
43 A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes Completed NCT02152371 Phase 3
44 Elastography Interest in the Management of Thyroid Nodules Completed NCT01335828 Phase 2, Phase 3
45 Iodine I-131 Iodocholesterol, Its Use in Adrenal Screening Completed NCT00037843 Phase 3
46 Acupuncture for the Treatment of Chronic Post-Chemotherapy Fatigue: A Randomized, Phase III Trial Completed NCT00200096 Phase 3
47 Soy Protein in Preventing Recurrent Cancer in Patients Who Have Undergone Surgery for Stage II Prostate Cancer Completed NCT00765479 Phase 2, Phase 3
48 A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer Completed NCT00762034 Phase 3
49 Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma Completed NCT00085735 Phase 3
50 EUS-Guided Pancreatic Injection of Cyst (EPIC) Trial Completed NCT00233038 Phase 2, Phase 3

Search NIH Clinical Center for Thyroid Cancer

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: thyroid neoplasms

Genetic Tests for Thyroid Cancer

Genetic tests related to Thyroid Cancer:

id Genetic test Affiliating Genes
1 Thyroid Carcinoma 29 24
2 Thyroid Cancer 29
3 Neoplasm of the Thyroid Gland 29

Anatomical Context for Thyroid Cancer

MalaCards organs/tissues related to Thyroid Cancer:

39
Thyroid, Lymph Node, Endothelial, Testes, Bone, Breast, Lung

Publications for Thyroid Cancer

Articles related to Thyroid Cancer:

(show top 50) (show all 2057)
id Title Authors Year
1
Changes in thyroid cancer incidence, post-2009 American Thyroid Association guidelines. ( 28092116 )
2017
2
Solid organ transplant and thyroid cancer. ( 28054336 )
2017
3
Effects of prolonged exposure to low dose metformin in thyroid cancer cell lines. ( 28529619 )
2017
4
Thyroid cancer screening. ( 28534740 )
2017
5
Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland. ( 27535135 )
2017
6
Thyroid cancer 1 (C8orf4) shows high expression, no mutation and reduced methylation level in lung cancers, and its expression correlates with I^-catenin and DNMT1 expression and poor prognosis. ( 28430656 )
2017
7
Genetics of medullary thyroid cancer: An overview. ( 28506408 )
2017
8
The relationship between iodine intake and the risk of thyroid cancer: A meta-analysis. ( 28514290 )
2017
9
PAPILLARY THYROID CANCER: THE GOOD AND BAD OF THE "GOOD CANCER". ( 28510505 )
2017
10
Morbidity of central compartment clearance: Comparison of lesser versus complete clearance in patients with thyroid cancer. ( 28508841 )
2017
11
Comprehensive gene and microRNA expression profiling reveals a role for miRNAs in the oncogenic roles of SphK1 in papillary thyroid cancer. ( 27942860 )
2017
12
Knockdown of SOX9 Inhibits the Proliferation, Invasion, and EMT in Thyroid Cancer Cells. ( 28277188 )
2017
13
Current Management of Low Risk Differentiated Thyroid Cancer and Papillary Microcarcinoma. ( 28087101 )
2017
14
Elevated Concentrations of SERPINE2/Protease Nexin-1 and Secretory Leukocyte Protease Inhibitor in the Serum of Patients with Papillary Thyroid Cancer. ( 28255192 )
2017
15
Intravoxel incoherent motion magnetic resonance imaging of the normal-appearing parotid glands in patients with differentiated thyroid cancer after radioiodine therapy. ( 28530137 )
2017
16
Management and outcome of clinically evident neck recurrence in patients with papillary thyroid cancer. ( 28516448 )
2017
17
Thyroid cancer: Overdiagnosis of papillary carcinoma - who benefits? ( 28059158 )
2017
18
Diagnostic and Treatment Patterns among Children, Adolescents and Young Adults with Thyroid Cancer in Ontario: 1992-2010. ( 28514192 )
2017
19
Cyp24a1 Attenuation Limits Progression of Braf(V600E) -Induced Papillary Thyroid Cancer Cells and Sensitizes Them to BRAF(V600E) Inhibitor PLX4720. ( 28242615 )
2017
20
Knockdown of lncRNA-PANDAR suppresses the proliferation, cell cycle and promotes apoptosis in thyroid cancer cells. ( 28507479 )
2017
21
MiR-221, a potential prognostic biomarker for recurrence in papillary thyroid cancer. ( 28061868 )
2017
22
Tall cell and diffuse sclerosing variants of papillary thyroid cancer: outcome and predicting value of risk stratification methods. ( 28528434 )
2017
23
CLINICOPATHOLOGICAL CHARACTERISTICS OF PAPILLARY THYROID CANCER IN CHILDREN WITH EMPHASIS ON THE PUBERTAL STATUS AND ASSOCIATION WITH BRAFV600E MUTATION. ( 28077340 )
2017
24
Elevated PTTG and PBF predicts poor patient outcome and modulates DNA damage response genes in thyroid cancer. ( 28504713 )
2017
25
MALDI-MSI Analysis of Cytological Smears: The Study of Thyroid Cancer. ( 28523498 )
2017
26
De novo thyroid cancer following solid organ transplantation-A 25-year experience at a high-volume institution with a review of the literature. ( 28054345 )
2017
27
Association of microRNA-related gene XPO5 rs11077 polymorphism with susceptibility to thyroid cancer. ( 28383405 )
2017
28
Deregulated expression of VHL mRNA variants in papillary thyroid cancer. ( 28089820 )
2017
29
"Pseudo-progression" in advanced thyroid cancer in response to kinase inhibitor therapy. ( 28509079 )
2017
30
Effect of Slug-Mediated Down-Regulation of E-Cadherin on Invasiveness and Metastasis of Anaplastic Thyroid Cancer Cells. ( 28070118 )
2017
31
MYH9 binds to lncRNA gene PTCSC2 and regulates FOXE1 in the 9q22 thyroid cancer risk locus. ( 28049826 )
2017
32
Pictorial Review of False-Positive Results on Radioiodine Scintigrams of Patients with Differentiated Thyroid Cancer. ( 28076008 )
2017
33
LMTK3 knockdown retards cell growth and invasion and promotes apoptosis in thyroid cancer. ( 28260052 )
2017
34
Knockdown of GATAD2A suppresses cell proliferation in thyroid cancer inA vitro. ( 28260108 )
2017
35
Low expression of long non-coding RNA GAS5 is associated with poor prognosis of patients with thyroid cancer. ( 28506768 )
2017
36
MiR-125b inhibits anaplastic thyroid cancer cell migration and invasion by targeting PIK3CD. ( 28122310 )
2017
37
Anti-thyroglobulin antibodies do not significantly increase the risk of finding iodine avid metastases on post-radioactive iodine ablation scan in low-risk thyroid cancer patients. ( 28510122 )
2017
38
Cytogenetic biodosimetry and dose-rate effect after radioiodine therapy for thyroid cancer. ( 28526978 )
2017
39
Systematic review of site distribution of bone metastases in differentiated thyroid cancer. ( 28079945 )
2017
40
Follow-up of patients with thyroglobulin-antibodies: Rising Tg-Ab trend is a risk factor for recurrence of differentiated thyroid cancer. ( 28509618 )
2017
41
Successful recovery from a subclavicular ulcer caused by lenvatinib for thyroid cancer: a case report. ( 28088233 )
2017
42
REFERRAL OF OLDER THYROID CANCER PATIENTS TO A HIGH-VOLUME SURGEON: RESULTS OF A MULTIDISCIPLINARY PHYSICIAN SURVEY. ( 28534681 )
2017
43
Thyroid function after TSH suppression for thyroid cancer: When is optimal time to check? ( 28504824 )
2017
44
Glycolysis-related protein expression in thyroid cancer. ( 28347233 )
2017
45
Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers. ( 26950846 )
2016
46
New drugs for medullary thyroid cancer: new promises? ( 27185870 )
2016
47
Thyroid Cancer Metabolism: A Review. ( 27213120 )
2016
48
TNF-I+ increases the membrane expression of the chemokine receptor CCR6 in thyroid tumor cells, but not in normal thyrocytes: potential role in the metastatic spread of thyroid cancer. ( 26577851 )
2016
49
Differences in miRNA and mRNA Profile of Papillary Thyroid Cancer Variants. ( 27656207 )
2016
50
Combined effect of Hashimoto's thyroiditis and BRAF(V600E) mutation status on aggressiveness in papillary thyroid cancer. ( 25213729 )
2016

Variations for Thyroid Cancer

ClinVar genetic disease variations for Thyroid Cancer:

6 (show all 32)
id Gene Variation Type Significance SNP ID Assembly Location
1 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
2 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
3 KRAS NM_033360.3(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
4 KRAS NM_004985.4(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
5 KRAS NM_004985.4(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913529 GRCh37 Chromosome 12, 25398284: 25398284
6 KRAS NM_033360.3(KRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
7 KRAS NM_033360.3(KRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic rs121913535 GRCh37 Chromosome 12, 25398282: 25398282
8 HRAS NM_005343.3(HRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
9 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
10 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
11 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
12 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
13 RET NM_020630.4(RET): c.1902C> G (p.Cys634Trp) single nucleotide variant Pathogenic/Likely pathogenic rs77709286 GRCh37 Chromosome 10, 43609950: 43609950
14 RET NM_020975.4(RET): c.2753T> C (p.Met918Thr) single nucleotide variant Pathogenic/Likely pathogenic rs74799832 GRCh37 Chromosome 10, 43617416: 43617416
15 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913364 GRCh37 Chromosome 7, 140453134: 140453134
16 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
17 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
18 BRAF NM_004333.4(BRAF): c.1802A> C (p.Lys601Thr) single nucleotide variant Pathogenic/Likely pathogenic rs397507484 GRCh37 Chromosome 7, 140453133: 140453133
19 KRAS NM_033360.3(KRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs121913240 GRCh37 Chromosome 12, 25380276: 25380276
20 KRAS NM_033360.3(KRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913240 GRCh37 Chromosome 12, 25380276: 25380276
21 KRAS NM_033360.3(KRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs17851045 GRCh37 Chromosome 12, 25380275: 25380275
22 KRAS NM_033360.3(KRAS): c.38G> T (p.Gly13Val) single nucleotide variant drug response rs112445441 GRCh37 Chromosome 12, 25398281: 25398281
23 PIK3CA NM_006218.3(PIK3CA): c.353G> A (p.Gly118Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587777790 GRCh38 Chromosome 3, 179199690: 179199690
24 PIK3CA NM_006218.3(PIK3CA): c.3129G> A (p.Met1043Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913283 GRCh37 Chromosome 3, 178952074: 178952074
25 KRAS NM_004985.4(KRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic rs121913238 GRCh37 Chromosome 12, 25380277: 25380277
26 NRAS NM_002524.4(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
27 NRAS NM_002524.4(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs121913255 GRCh37 Chromosome 1, 115256528: 115256528
28 NRAS NM_002524.4(NRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
29 HRAS; LRRC56 NM_005343.3(HRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
30 KRAS NM_004985.4(KRAS): c.437C> T (p.Ala146Val) single nucleotide variant Pathogenic rs1057519725 GRCh37 Chromosome 12, 25378561: 25378561
31 KRAS NM_004985.4(KRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913240 GRCh37 Chromosome 12, 25380276: 25380276
32 KRAS NM_033360.3(KRAS): c.37G> A (p.Gly13Ser) single nucleotide variant Pathogenic rs121913535 GRCh37 Chromosome 12, 25398282: 25398282

Copy number variations for Thyroid Cancer from CNVD:

7 (show all 22)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 48476 11 1 43400000 Gain Thyroid cancer
2 75266 13 18400000 72100000 Loss Thyroid cancer
3 80538 13 93800000 114142980 Loss Thyroid cancer
4 85051 14 37800000 43500000 Copy number FOXA1 Thyroid cancer
5 96631 15 90931472 91045475 Amplificationlicatio n IQGAP1 Thyroid cancer
6 111285 17 35400000 68400000 Gain Thyroid cancer
7 120295 18 23300000 71300000 Loss Thyroid cancer
8 150420 20 1 27100000 Amplification Thyroid cancer
9 151957 20 27100000 62435964 Amplification Thyroid cancer
10 153452 20 37100000 62435964 Gain Thyroid cancer
11 171643 3 170900000 182700000 Gain PIK3CA Thyroid cancer
12 171644 3 170900000 182700000 Gain PIK3CA Thyroid cancer
13 191662 5 1 45800000 Amplification Thyroid cancer
14 191664 5 1 45800000 Gain Thyroid cancer
15 200481 5 55800000 180857866 Gain Thyroid cancer
16 201091 5 65300000 159900000 Amplification Thyroid cancer
17 217036 7 1 158821424 Amplification Thyroid cancer
18 230743 8 1 19100000 Loss Thyroid cancer
19 236403 8 16100000 117700000 Amplification Thyroid cancer
20 236404 8 16100000 146274826 Gain Thyroid cancer
21 261707 X 24900000 59500000 Loss Thyroid cancer
22 303365 21 26028751 26066642 Deletion NRF2 Thyroid cancer

Expression for Thyroid Cancer

Search GEO for disease gene expression data for Thyroid Cancer.

Pathways for Thyroid Cancer

Pathways related to Thyroid Cancer according to KEGG:

37
id Name Kegg Source Accession
1 Thyroid cancer hsa05216

Pathways related to Thyroid Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.83 BRAF HRAS KRAS NRAS PPARG
2
Show member pathways
12.81 BRAF CDH1 HRAS KRAS NRAS NTRK1
3
Show member pathways
12.74 BRAF CDH1 HRAS KRAS NRAS
4 12.72 BRAF HRAS KRAS NRAS NTRK1
5
Show member pathways
12.57 BRAF CDH1 HRAS KRAS NRAS
6
Show member pathways
12.44 HRAS KRAS NRAS NTRK1
7
Show member pathways
12.4 BRAF HRAS KRAS NRAS
8
Show member pathways
12.39 PAX8 SLC5A5 TG TPO TSHR
9
Show member pathways
12.38 BRAF HRAS KRAS NRAS
10
Show member pathways
12.34 BRAF HRAS KRAS NRAS
11
Show member pathways
12.33 BRAF CDH1 HRAS KRAS NRAS
12
Show member pathways
12.31 BRAF HRAS KRAS NRAS
13 12.3 BRAF HRAS KRAS NRAS
14
Show member pathways
12.3 BRAF HRAS KRAS NRAS
15 12.29 BRAF CCDC6 CDH1 HRAS KRAS NCOA4
16
Show member pathways
12.27 BRAF HRAS KRAS NRAS
17
Show member pathways
12.24 BRAF HRAS KRAS NRAS PPARG
18
Show member pathways
12.21 BRAF HRAS KRAS NRAS
19
Show member pathways
12.2 HRAS KRAS NRAS RET
20
Show member pathways
12.15 HRAS KRAS NRAS PPARG
21
Show member pathways
12.11 BRAF HRAS KRAS NRAS
22
Show member pathways
12.11 BRAF HRAS KRAS NRAS PPARG
23 12.1 CDH1 HRAS KRAS NRAS
24
Show member pathways
12.1 BRAF HRAS KRAS NRAS
25
Show member pathways
12.09 BRAF HRAS KRAS NRAS
26 12.06 BRAF HRAS KRAS NRAS
27
Show member pathways
12.04 BRAF HRAS KRAS NRAS NTRK1
28 12.03 CDH1 HRAS KRAS NRAS
29 11.99 BRAF HRAS KRAS NRAS
30 11.96 BRAF HRAS KRAS NRAS
31 11.94 BRAF HRAS KRAS NRAS
32
Show member pathways
11.85 HRAS KRAS NRAS
33
Show member pathways
11.85 HRAS KRAS NRAS
34 11.83 HRAS KRAS NRAS
35 11.75 BRAF HRAS KRAS NRAS NTRK1
36
Show member pathways
11.69 BRAF HRAS KRAS NRAS RET
37 11.68 HRAS KRAS NRAS
38 11.67 BRAF HRAS PAX8 TSHR
39
Show member pathways
11.64 BRAF HRAS KRAS NRAS
40 11.61 HRAS KRAS NRAS
41 11.58 BRAF CDH1 HRAS KRAS NRAS
42 11.57 BRAF HRAS KRAS NRAS
43 11.47 HRAS KRAS NRAS NTRK1 RET
44 11.42 HRAS KRAS NRAS RET
45 11.28 HRAS KRAS NRAS
46 11.28 HRAS KRAS NRAS
47
Show member pathways
11.25 HRAS KRAS NRAS
48 11.24 BRAF HRAS KRAS NRAS
49
Show member pathways
11.18 HRAS KRAS NRAS
50 11.11 HRAS KRAS NRAS

GO Terms for Thyroid Cancer

Biological processes related to Thyroid Cancer according to GeneCards Suite gene sharing:

(show all 18)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.89 BRAF HRAS KRAS NKX2-1 RET
2 positive regulation of transcription, DNA-templated GO:0045893 9.8 CDH1 FOXE1 NCOA4 NKX2-1 PAX8 PPARG
3 MAPK cascade GO:0000165 9.77 BRAF HRAS KRAS NRAS RET
4 negative regulation of neuron apoptotic process GO:0043524 9.76 BRAF HRAS KRAS NTRK1
5 Ras protein signal transduction GO:0007265 9.72 HRAS KRAS NRAS
6 epidermal growth factor receptor signaling pathway GO:0007173 9.69 HRAS KRAS NRAS
7 ERBB2 signaling pathway GO:0038128 9.61 HRAS KRAS NRAS
8 detection of temperature stimulus involved in sensory perception of pain GO:0050965 9.58 CALCA NTRK1
9 cellular response to nerve growth factor stimulus GO:1990090 9.58 BRAF CALCA NTRK1
10 hormone biosynthetic process GO:0042446 9.57 TG TPO
11 positive regulation of adenylate cyclase activity GO:0045762 9.56 CALCA TSHR
12 response to isolation stress GO:0035900 9.54 HRAS KRAS
13 cellular response to gonadotropin stimulus GO:0071371 9.52 PAX8 SLC5A5
14 iodide transport GO:0015705 9.48 SLC5A5 TG
15 axon guidance GO:0007411 9.43 HRAS KRAS NKX2-1 NRAS NTRK1 RET
16 thyroid hormone generation GO:0006590 9.33 FOXE1 SLC5A5 TPO
17 thyroid-stimulating hormone signaling pathway GO:0038194 9.32 PAX8 TSHR
18 thyroid gland development GO:0030878 9.02 BRAF FOXE1 NKX2-1 PAX8 TG

Molecular functions related to Thyroid Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein complex binding GO:0032403 9.46 CALCA KRAS NRAS TSHR
2 nucleotide binding GO:0000166 9.35 BRAF HRAS KRAS NRAS RET
3 thyroid-stimulating hormone receptor activity GO:0004996 8.62 PAX8 TSHR

Sources for Thyroid Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....